Struktur-Biomarker zur Früherkennung von Morbus Alzheimer


lzheimer’s disease cannot be cured today. In addition to a drug, a
predictive blood biomarker is urgently needed to identify high-risk
subjects in early cognitively less impaired stages. Here, a biomarker is
presented that uses the secondary structure distribution of Aβ-peptides
in blood measured by the immuno-infrared sensor. Using this
structure-based biomarker clinical conversion of symptomless subjects
at baseline were predicted in a follow-up study 14 years before